Journal
EXPERT REVIEW OF NEUROTHERAPEUTICS
Volume 10, Issue 12, Pages 1811-1825Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERN.10.73
Keywords
biomarkers; genomic; motor; neurochemical; neuroimaging; non-motor; Parkinson's disease
Categories
Funding
- Singapore General Hospital
- National Neuroscience Institute
- Duke-NUS Graduate Medical School, Singapore
- Millennium Foundation
- National Medical Research Council
Ask authors/readers for more resources
Parkinson's disease (PD) is the most common neurodegenerative movement disorder, affecting over 6 million people worldwide. It is anticipated that the number of affected individuals may increase significantly in the most populous nations by 2030. During the past 20 years, much progress has been made in identifying and assessing various potential clinical, biochemical, imaging and genetic biomarkers for PD. Despite the wealth of information, development of a validated biomarker for PD is still ongoing. It is hoped that reliable and well-validated biomarkers will provide critical clues to assist in the diagnosis and management of Parkinson's disease patients in the near future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available